Scientists in Chicago have made a surprising discovery that could change how doctors fight cancer. A team at Northwestern Medicine found that a tiny receptor in the immune system — called the A2A receptor — plays a confusing double role in weakening the body's ability to attack tumors. Their findings, published in the journal Proceedings of the National Academy of Sciences, help explain why some recent cancer drug trials haven't worked as well as hoped.
CD8+ T-cells are the foot soldiers of the immune system. They patrol the body looking for viruses, bacteria, and even cancer cells. But in chronic illness and cancer, these cells can wear out over time — a state scientists call T-cell exhaustion. When T-cells become exhausted, they stop doing their job properly, allowing diseases to take hold.
For years, researchers believed the A2A receptor acted like a brake on T-cells. When tumor environments become low on oxygen (a condition called hypoxia), this receptor kicks in and slows down the immune response. Several recent clinical trials tested drugs that block this receptor, hoping to release the brake and let T-cells fight cancer again. But the trials showed only limited success in treating solid tumors like prostate cancer and kidney cancer.
Now, Dr. Bin Zhang and his team have discovered why those trials struggled. Using a powerful technique called single-cell multiomics profiling, they found that the A2A receptor doesn't work in a simple, one-way manner. Instead, it plays a dual role: both having too much of this receptor AND having too little of it can push T-cells toward exhaustion, just through different biological pathways.
"This discovery really challenges the traditional view of this emerging immune checkpoint molecule," said Zhang, the Johanna Dobe Professor of Cancer Immunology at Northwestern. "It actually uncovers a complex, context-dependent dynamic where too much or too little receptor activity drives T-cells toward a terminal dysfunctional state over time."
The team also identified a protein called CD122 that helps drive exhaustion when the A2A receptor is missing. When they genetically deleted CD122 in mice with depleted A2A receptors, the T-cell exhaustion actually improved — suggesting this protein could be another target for future treatments.
The findings point to a new approach: instead of simply blocking the A2A receptor completely, doctors may need to fine-tune its activity — finding the sweet spot where T-cells stay strong enough to fight cancer without becoming exhausted. Zhang said he hopes this work will inspire researchers to redesign clinical trials with this new understanding in mind.
"We can reconsider A2AR blockade strategies to improve the design of clinical trials," Zhang said. "That's something we're really looking forward to in the next stage of this work."